Global Health Limited reported a strong operating performance in Q3 FY26, with consolidated total income rising 19.1% year-on-year to ₹11,428 million, reflecting robust patient volumes, improved realizations and steady execution across its hospital network.
EBITDA excluding the newly commissioned Noida hospital grew 10.9% to ₹2,814 million, with healthy margins of 25.4%. However, consolidated EBITDA including Noida declined 1.7% to ₹2,494 million, as the Noida facility—operational since September 2025—posted revenue of ₹343 million and an EBITDA loss of ₹320 million during the quarter. Consolidated margins stood at 21.8%.
Profit after tax for the quarter came in at ₹950 million, impacted by depreciation and finance costs related to Noida, initial operating losses, and a non-recurring exceptional expense of ₹366 million due to the statutory implementation of new Labour Codes.
Operational metrics remained firm, with inpatient volumes rising 14.3% and outpatient volumes up 19.5% year-on-year. Average length of stay improved 6.6% to 3.02 days, ARPOB increased 9.9% to ₹67,361, and occupancy stood at around 59% on expanded capacity. The company added 144 beds during the quarter.
For 9M FY26, total income rose 17.6% to ₹33,131 million, EBITDA (including Noida) increased 8% to ₹7,654 million, and PAT grew 8.5% to ₹4,124 million, supported by strong growth in developing hospitals, international patient revenue, and OPD pharmacy sales.
